Express Diagnostics Int'l, Inc. (EDI), has announced that its patent for the DrugCheck SalivaScan Oral Fluid Drug Test, titled “Device for Verifying Analytes in Bodily Fluids,” was approved by the European Patent Office. The patent is currently pending with the U.S. Patent and Trademark Office.
“I am more than elated to announce that the first of many patents for the DrugCheck SalivaScan Oral Fluid Drug Test—the European patent—has been granted and published,” says Paul Johnson, CEO of Express Diagnostics Int'l, Inc. “With the issuance of the European patent, we fully expect the U.S. patent to be granted and published in early 2015.”
Features of the DrugCheck SalivaScan include an integrated sponge saturation indicator in the collection swab that notifies test administrators when sufficient specimen has been collected. Company representatives say that determining adequate specimen according to the color change on the indicator strip helps reduce the potential costs of test failure due to insufficient specimen often associated with competing saliva devices.
The collection swab locks into the DrugCheck SalivaScan for a tamper-evident seal. The device can then be sent to a laboratory for confirmation on a presumptive positive result. Dual side extraction ports simplify specimen access for laboratory personnel.
The device can screen simultaneously for up to 10 drugs of abuse, with 16 total available, including market-leading cutoffs, or detection levels, for buprenorphine, cotinine, EDDP, ketamine, and methadone. The DrugCheck SalivaScan is for Forensic Use or export only. Forensic Use in the U.S. is limited to criminal justice or government agencies, including correction centers, court systems, jails, police departments, probation offices, the Department of Defense, U.S. military, and laboratories performing forensic testing for these entities.
Read more on the Express Diagnostics website
